Welcome to our dedicated page for Denali Therapeutics SEC filings (Ticker: DNLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Denali Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Denali Therapeutics's regulatory disclosures and financial reporting.
Denali Therapeutics director Peter S. Klein reported equity awards consisting of restricted stock units and stock options. He received 6,408 shares of Common Stock in the form of RSUs, with all RSUs scheduled to vest in full on the earlier of the one-year anniversary of the grant date or the day before the company’s next annual stockholder meeting after the grant date.
He was also granted a stock option covering 19,226 shares of Common Stock at an exercise price of $19.66 per share, with the option vesting on the same schedule as the RSUs. Following these awards, Klein directly owns 33,941 shares of Common Stock and holds the newly granted option for 19,226 underlying shares.
Denali Therapeutics director Steve E. Krognes reported equity awards and updated holdings. He received 6,408 shares of common stock in the form of Restricted Stock Units, which will vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali’s next annual stockholder meeting. He was also granted stock options for 19,226 shares at an exercise price of $19.66 per share, with the same vesting schedule and an expiration date in 2036. Following these grants, he holds 38,202 shares directly and 781,797 shares indirectly through The Steve Edward Krognes Revocable Trust, where he serves as trustee.
Denali Therapeutics director David P. Schenkein reported new equity awards. He received 6,408 Restricted Stock Units, each representing a contingent right to one share of common stock. These RSUs vest in full on the earlier of one year from grant or the day before the next annual stockholder meeting.
He also received a stock option for 19,226 shares at an exercise price of $19.66 per share, with the same vesting schedule. After these grants, he directly holds 21,665 common shares, and additional common shares are held indirectly through the David P. Schenkein 2004 Revocable Trust and the Amy P. Schenkein 2004 Revocable Trust.
Denali Therapeutics Inc. director Nancy Thornberry reported routine equity compensation awards. She received 6,408 Restricted Stock Units, each tied to one share of common stock, which will fully vest on the earlier of one year from grant or the day before the next annual stockholder meeting.
She was also granted a stock option for 19,226 shares of common stock at an exercise price of $19.66 per share, with the same vesting schedule and expiration in 2036. Following these awards, she directly holds 31,125 shares of common stock, including the unvested RSUs.
Denali Therapeutics director Timothy Van Hauwermeiren received new equity awards as part of his compensation. He was granted 6,408 shares of common stock in the form of Restricted Stock Units (RSUs), each representing a contingent right to one share of Denali common stock.
All of these RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali’s next annual meeting of stockholders. After this grant, he holds 17,040 RSUs in total, which are all unvested. He was also granted options to purchase 19,226 shares of common stock at an exercise price of $19.66 per share, vesting on the same schedule and expiring in 2036.
Denali Therapeutics director Jennifer E. Cook received equity compensation consisting of restricted stock units and stock options. She acquired 6,408 shares of Common Stock at a price of $0.00 per share as a grant, bringing her direct Common Stock holdings to 32,483 shares.
Each of these 6,408 shares is represented by a restricted stock unit and a contingent right to receive one share of Common Stock, with 100% of the units vesting upon the earlier of the one-year anniversary of the grant date or the day preceding Denali’s next annual meeting of stockholders. She also received a stock option covering 19,226 shares of Common Stock at an exercise price of $19.66 per share, which will vest on the same schedule.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Denali Therapeutics Inc. director Julian C. Baker received equity-based compensation linked to Baker Brothers funds. The filing reports a grant of 6,408 restricted stock units payable in Denali common stock and 19,226 non-qualified stock options exercisable into common stock at a strike price of $19.66 per share. Both the RSUs and options vest on the earlier of June 3, 2027 or the day prior to Denali’s next annual meeting after June 3, 2026, subject to his continued board service. The transactions are reported as indirect interests of 667, L.P. and Baker Brothers Life Sciences, L.P., with Baker Bros. Advisors LP holding voting and dispositive power. Felix and Julian Baker, the adviser and its general partner all disclaim beneficial ownership beyond their indirect pecuniary interests.
Denali Therapeutics Inc. reported the results of its annual stockholder meeting held on June 3, 2026. Of the 158,675,498 shares of common stock outstanding as of April 9, 2026, 137,986,127 were represented in person or by proxy, representing 86.96% of shares entitled to vote.
Stockholders elected three Class III directors to serve until the 2029 annual meeting: Jennifer Cook, David Schenkein, M.D., and Ryan Watts, Ph.D. Each received more votes “for” than “withheld,” with Ryan Watts, Ph.D. receiving 121,220,572 votes in favor.
Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 137,516,267 votes for, 420,305 against, and 49,555 abstentions. In an advisory vote, stockholders approved the compensation of the named executive officers, with 117,038,745 votes for and 7,088,810 against.
Denali Therapeutics Inc. and Biogen reported topline results from the Phase 2b LUMA study of BIIB122 (DNL151) in early-stage Parkinson’s disease. The study did not meet its primary endpoint of time to confirmed worsening on the MDS-UPDRS Part II and III combined score, and secondary endpoints also showed no benefit versus placebo.
Based on these results, the companies will discontinue development of BIIB122 in idiopathic Parkinson’s disease. Denali will continue to run the separate Phase 2a BEACON study in individuals with Parkinson’s disease who carry a pathogenic LRRK2 variant, with data anticipated in the first half of 2027.
T. Rowe Price Investment Management, Inc. files a Schedule 13G reporting beneficial ownership of 8,519,192 shares of Denali Therapeutics common stock.
The filing states this represents 5.4% of the class as of 03/31/2026, and shows sole voting power of 8,503,878 and sole dispositive power of 8,519,192. The filing is signed on 05/15/2026.